Psoriasis Treatment

With the enormous amount of information on psoriasis today, it can be intimidating to try to update not only for new therapies to keep, but its advantages and disadvantages.

Without this information, you can not really an informed decision about what you discuss with your doctor and what direction you want in their attempt to explore their psoriasis symptoms. A new group of biological drugs, systemic medications) are (by mouth or injected.

The latest and greatest:

Break in patients with moderate psoriasis plaque on new treatment options recently approved by the Food and Drug Administration of the United States: alefacept, efalizumab and etanercept. One of them has received the approval of etanercept to treat psoriatic arthritis, a new hope for patients as well. The new biologics have been developed to ensure that other systemic medications, especially liver or kidney failure can cause long-term use of older drugs.

New treatments for psoriasis are injection

1. Alefacept. The standard treatment trial of 12 weeks seems to be more effective with longer periods of remission when treatment is administered for a longer period of 16 weeks. Side effects (mild and include infection, reaction at the injection site, itching, and flu-like symptoms) did not show a significant increase over a longer period compared to normal time at table. Repeat Courses of alefacept to prove safe and effective way. In addition to the treatment of plaque psoriasis, the drug appears effective in palmoplantar psoriasis after 12 weeks of treatment, allowing patients to walk without pain and use her hands again. It is also very early in treatment during therapy withdrawal alefacept other.

2. Efalizumab. Studies have shown that treatment for psoriasis proved safe and effective for continuous treatment of up to 60 weeks without fear of toxicity. No new side effects were manifested as worsening side effects not observed with shorter treatment periods. These side effects are headache, chills, fever and nausea.

3. Etanercept. The biological treatment was used for the treatment of plaque psoriasis and psoriatic arthritis, rheumatoid arthritis and was found healthy long-term treatment of these patients. An important factor is important to note that there seems to have a relapse within three months after the end of the dose in the treatment of psoriasis, but the deadline for withdrawal is not a serious outbreak of symptoms. Food processing is also effective without increasing side effects. Unlike the methods of treatment with etanercept for rheumatoid arthritis, psoriasis is recommended at irregular intervals or in rotation with other treatments.

New oral treatments for psoriasis are as follows:

1. Therapy ester of fumaric acid. Introduced it almost 30 years ago, is one of the German treatment most commonly prescribed orally for cutting plaque psoriasis. Common side effects include rashes, diarrhea, abdominal pain and nausea. Kidneys, decreased white blood cell count and osteoporosis are serious side effects of this treatment of psoriatic arthritis. Gastro-intestinal, 37% of those under the original or drug use, however, the recent redefinition offers only rare cases of gastro-intestinal.

2. Oral pimecrolimus. The treatment of psoriasis consists of two fronts, both with incredible results and terrible side effects. 2003 Studies of the results of the repeated drug treatments show quite clearly the symptoms of psoriasis, which in 28 days, the new fab for those affected in psoriasis. In June 2006, the FDA issued a press release sent to a possible dose dependent relationship between oral pimecrolimus and lymphomas. This is based on animal studies that were conducted begun as a result of 10 human cases of patients after initiation of treatment. It is still determining if it is a direct relationship or not, and it may take 10 years or more human studies to determine whether a link exists between this treatment and psoriasis there is cancer. Based on these findings, guidelines from the FDA for the use of this treatment was given:

A. Use only as second line agent for short-term and intermittent treatment of patients refractory to or intolerant of other treatments.

B. Avoid use in children under 2 years. The effects on the developing immune system in infants and children is not known. In clinical trials, infants and children under 2 years with a higher rate of infections of upper respiratory tract were treated with placebo cream.

C. Use only for a short period of time, continuously.

D. Do not use in patients whose immune systems are weakened or undermined.

E. use the minimum necessary to control symptoms of the patient.



Technorati Tag: psoriasis treatment